Cargando…

Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma

The incidence of metastatic pheochromocytoma (PHEO) and paraganglioma (PGL) may occur in as many as 35% of patients particularly with PGL and even more frequently in those with specific mutations. Biochemical, morphological, and molecular markers have been investigated for use in the distinction of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ilanchezhian, Maran, Jha, Abhishek, Pacak, Karel, Del Rivero, Jaydira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Neuroendocrine Cancers (JR Strosberg, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456409/ https://www.ncbi.nlm.nih.gov/pubmed/32862332 http://dx.doi.org/10.1007/s11864-020-00787-z

Ejemplares similares

MON-214 Biochemical Abnormalities in Endocrine Function Associated with Lutetium 177-DOTATATE Therapy in Metastatic Pheochromocytoma and Paraganglioma
por: Gubbi, Sriram, et al.
Publicado: (2020)

Clinical Presentation and Outcomes of Phaeochromocytomas/Paragangliomas in Neurofibromatosis Type 1
por: Al-Sharefi, Ahmed, et al.
Publicado: (2019)

Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches
por: Kuo, Mickey J. M., et al.
Publicado: (2022)

New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications
por: Jhawar, Sakshi, et al.
Publicado: (2022)

SAT305 Clinical Characteristics And Outcomes Of Patient With Metastatic Pheochromocytoma/Paraganglioma (PPGL) And Extreme Elevated Biochemistry
por: Prodanov, Tamara, et al.
Publicado: (2023)

Performances of Functional and Anatomic Imaging Modalities in Succinate Dehydrogenase A-Related Metastatic Pheochromocytoma and Paraganglioma
por: Patel, Mayank, et al.
Publicado: (2022)

Pheochromocytoma (PHEO) and Paraganglioma (PGL)
por: Pacak, Karel, et al.
Publicado: (2019)

New insights on the pathogenesis of paraganglioma and pheochromocytoma
por: Kantorovich, Vitaly, et al.
Publicado: (2018)

SAT329 Case Series Of Patients With FGFR-1 Related Pheochromocytoma With A Focus On Biochemical And Imaging Signatures
por: Jhawar, Sakshi, et al.
Publicado: (2023)

Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World
por: Patel, Mayank, et al.
Publicado: (2021)

PSUN27 Largest Cohort of Cervical Spine Metastases of Pheochromocytoma/Paraganglioma in the Setting of SDHB Mutation
por: Pacak, Karel, et al.
Publicado: (2022)

The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study
por: Schovanek, Jan, et al.
Publicado: (2014)

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma
por: Gubbi, Sriram, et al.
Publicado: (2021)

Personalized Management of Pheochromocytoma and Paraganglioma
por: Nölting, Svenja, et al.
Publicado: (2021)

Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging
por: Blanchet, Elise M., et al.
Publicado: (2012)

Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies
por: Pang, Ying, et al.
Publicado: (2019)

Postoperative Management in Patients with Pheochromocytoma and Paraganglioma
por: Mamilla, Divya, et al.
Publicado: (2019)

Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma
por: Jha, Abhishek, et al.
Publicado: (2019)

Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [(177)Lu]Lu-DOTA-TATE therapy
por: Gubbi, Sriram, et al.
Publicado: (2023)

SAT-502 Clinical Hypothyroidism Associated with Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma: A Novel Adverse Effect of Peptide Receptor Radionuclide Therapy
por: Gubbi, Sriram, et al.
Publicado: (2020)

High-Throughput Screening for the Identification of New Therapeutic Options for Metastatic Pheochromocytoma and Paraganglioma
por: Giubellino, Alessio, et al.
Publicado: (2014)

OR29-6 Brown Adipose Tissue Activation in SDHx-Related Pheochromocytoma and Paraganglioma: An Ominous Sign?
por: Abdul Sater, Zahraa, et al.
Publicado: (2019)

Metastatic Pheochromocytomas and Abdominal Paragangliomas
por: Granberg, Dan, et al.
Publicado: (2021)

Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma
por: Calsina, Bruna, et al.
Publicado: (2023)

Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma
por: Zhang, Liang, et al.
Publicado: (2023)

Genome analysis identifies differences in the transcriptional targets of duodenal versus pancreatic neuroendocrine tumours
por: Rico, Karen, et al.
Publicado: (2021)

Severe hyponatremia as presenting symptom of small cell lung carcinoma
por: Stevchevska, Aleksandra, et al.
Publicado: (2023)

A rare case of ectopic Cushing syndrome presenting with weight loss
por: Şah Ünal, Fatma Tuğçe, et al.
Publicado: (2023)

A case of malign insulinoma diagnosed with liver metastasis
por: Şehit Kara, Canan, et al.
Publicado: (2023)

Pancreatic tumor with hepatic metastases secreting vasoactive intestinal polypeptide: Treatment options and long-term follow-up results
por: Sözen, Mehmet, et al.
Publicado: (2023)

Mutational Profile of Metastatic Pheochromocytoma and Paraganglioma
por: Choi, Yun Mi, et al.
Publicado: (2021)

Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma
por: Mollazadegan, Kazhan, et al.
Publicado: (2021)

New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms
por: Fortunati, Emilia, et al.
Publicado: (2022)

Surgical Principles in the Management of Lung Neuroendocrine Tumors: Open Questions and Controversial Technical Issues
por: Brascia, Debora, et al.
Publicado: (2022)

Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study
por: Bratslavsky, Gennady, et al.
Publicado: (2021)

SAT-LB311 Inoperable, Metastatic Pheochromocytoma & Paraganglioma Tumor Size Reduction After Lu-177-dotatate (Lutathera®) Treatment Trial: The Role of Nursing
por: Ude, Assumpta, et al.
Publicado: (2020)

PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma
por: Hadrava Vanova, Katerina, et al.
Publicado: (2022)

Adrenocortical carcinoma masquerading as pheochromocytoma: a histopathologic dilemma
por: Shetty, Impana, et al.
Publicado: (2019)

Reactive Oxygen Species: A Promising Therapeutic Target for SDHx-Mutated Pheochromocytoma and Paraganglioma
por: Hadrava Vanova, Katerina, et al.
Publicado: (2021)

External Beam Radiation Therapy in Treatment of Malignant Pheochromocytoma and Paraganglioma
por: Vogel, Jennifer, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o8fb8mbts0n0i57hqnbgs519ar